TPI-1 treatment reduces T cell exhaustion while increasing activation of CD8+ tumor-infiltrating lymphocytes in PD-1/PD-L1 blockade-resistant 344SQ lung tumors (93). The gene discussed is CD8A; the disease is neoplasm.